A Comparison of Two Cognitive Batteries in People With Schizophrenia
NCT00499044 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2009-11-26
Summary
The investigators will compare the test-retest reliabilities of two cognitive batteries in people with schizophrenia: Cognitive Drug Research Computerized Cognitive Assessment System ("CDR") and MATRICS Consensus Cognitive Battery ("MCCB"). The investigators hypothesize that there will be a statistically significant difference in the test-retest reliabilities between MCCB and CDR. In addition, the investigators hypothesize that each of the two batteries will better measure certain areas of cognition. The investigators also hypothesize that scores from both batteries will correlate with quality of life scores, and that there will be a significant difference between the correlations of MCCB and CDR. The investigators hypothesize there will be a significant difference in patients' self-reported tolerability and satisfaction of the MATRICS versus CDR assessments. Lastly, the investigators hypothesize that there will be a significant difference in the MATRICS versus CDR batteries with respect to an administrator-rated score of practicality.
Approximately 32 subjects will enroll in the study. Following consent and eligibility screening (visit 1) and baseline clinical assessment and training in the use of the CDR battery (visit 2), subjects will be randomized into one of two groups for visits 3 and 4. One group will complete the CDR and then MCCB in visit 3, as well as the Tolerability Scale for each battery. The other group will complete the batteries in reverse order during visit 3. Each group will complete both batteries again in reverse order for visit 4. Randomization will be done in blocks of 2. After completion of every 4 subjects, study administrators will complete the Practicality Scale for each battery.
Conditions
- Schizophrenia
- Schizoaffective Disorder
Interventions
- OTHER
-
CDR Computerized Cognitive Assessment System
Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
- OTHER
-
MATRICS Consensus Cognitive Battery
The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
Sponsors & Collaborators
-
North Suffolk Mental Health Association
lead OTHER
Principal Investigators
-
A. Eden Evins, M.D., M.P.H. · Massachusetts General Hospital
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-12-31
- Primary Completion
- 2009-03-31
- Completion
- 2009-03-31
Countries
- United States
Study Locations
More Related Trials
-
Treatment Study for Cognitive Deficits in Schizophrenia
NCT00505076 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
NCT01555697 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Brain Imaging, Attention, and Auditory Processing in Schizophrenia
NCT03068806 ·Status: COMPLETED
-
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01655680 ·Status: COMPLETED ·Phase: PHASE2
-
Predictors of Response to Cognitive Remediation in Schizophrenia
NCT00333970 ·Status: COMPLETED ·Phase: NA
-
Promoting Cognitive Health in Schizophrenia
NCT05661448 ·Status: RECRUITING ·Phase: NA
-
Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia
NCT01545999 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers
NCT01788436 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
NCT03807882 ·Status: COMPLETED ·Phase: PHASE4
-
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT03649581 ·Status: RECRUITING ·Phase: NA
-
Neurophysiological Targets for Cognitive Training in Schizophrenia
NCT00923078 ·Status: COMPLETED ·Phase: NA
-
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
NCT02237235 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
NCT01834638 ·Status: TERMINATED ·Phase: PHASE2
-
Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia
NCT05435300 ·Status: RECRUITING
-
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01678755 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
NCT03166098 ·Status: COMPLETED
-
Improving Accessibility and Personalization of CR for Schizophrenia
NCT03576976 ·Status: COMPLETED ·Phase: NA
-
Investigation of Objective Cognitive Effort in Neuropsychological Evaluation of Psychotic Disorders
NCT06782672 ·Status: NOT_YET_RECRUITING
-
Cerebellar Modulation of Cognition in Psychosis
NCT06107764 ·Status: RECRUITING ·Phase: NA
-
Cognitive Remediation in Schizophrenia
NCT01903707 ·Status: UNKNOWN ·Phase: NA
-
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
NCT04857983 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
fMRI Cholinergic Mechanisms in Schizophrenia
NCT01191827 ·Status: COMPLETED
-
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
NCT00509067 ·Status: COMPLETED ·Phase: PHASE2
-
CVN058 Effect on Mismatch Negativity in Schizophrenics
NCT03669250 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
NCT00097942 ·Status: COMPLETED ·Phase: PHASE2